Document is current
Any future updates will be listed below
-
Authors
Weeks, S.
Brown, A.
Doughty, K.
Armstrong-James, D.
Bennett, N.
Birch, M.
Borman, A. M.
Bromley, M.
Bryson, R.
Fisher, M. C.
Freeman, D.
Grimmer, M.
Rex, J. H.
West, H.
White, P. L.
Bottery, M. J.
-
Funding
Funding for this research was provided by:
Grand Union Doctoral Training Partnership (ES/P000649/1)
Biotechnology and Biological Sciences Research Council (BB/Z515619/1)
Biotechnology and Biological Sciences Research Council (BB/Z515619/1)
Biotechnology and Biological Sciences Research Council (BB/Z515619/1)
Biotechnology and Biological Sciences Research Council (BB/Z515619/1)
Biotechnology and Biological Sciences Research Council (BB/Z515619/1)
Biotechnology and Biological Sciences Research Council (BB/Z515619/1)
Department of Health and Social Care’s Global AMR Innovation Fund (FR1-57)
Department of Health and Social Care’s Global AMR Innovation Fund (FR1-57)
Medical Research Council (MR/Y034465/1)
Canadian Institute for Advanced Research
Wellcome Trust (320833/Z/24/Z)
- License Information
-
More Information
Article History
Received: 24 February 2026
Accepted: 13 May 2026
First Online: 29 May 2026
Competing interests
: During the period 2024–2026, J.H.R., MD, is/has been Chief Medical Officer & Director, F2G, Ltd., Editor-in-Chief, AMR.Solutions, Operating Partner & Consultant, Advent Life Sciences, and Adjunct Professor of Medicine, McGovern Medical School, Houston, TX; has received grant support from Wellcome Trust; and has served on the scientific advisory board of the AMR Action Fund (AMRAF). He is currently a shareholder in AstraZeneca Pharmaceuticals, F2G, Ltd, and Advent Life Sciences. The opinions expressed are his own and do not necessarily reflect the opinion of any of the groups with which he works. M.Bi. is an employee and shareholder of F2G Ltd. K.D. is a crop protection consultant, currently advising CropLife International, the trade association representing the major R&D crop protection companies. The opinions expressed are his own and do not necessarily reflect the opinions of the association. D.A.J. holds stock options in Pulmocide Ltd. P.L.W is a consultant for IMMY, Ltd and provided the central mycology laboratory services for the F2G phase II and phase III clinical trials. The other authors do not have a competing interest.
